Period prevalence and risk factors for postoperative short-term wound complications in vulvar cancer: A cross-sectional study

International Journal of Gynecological Cancer

Volumn 20, Issue 4, 2010, Pages 646-654

  Senn, Beate ^a,b   Mueller, Michael David ^b   Cignacco, Eva Lucia ^a   Eicher, Manuela ^b,c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Haute École D'ingénierie et D'architecture de Fribourg ROSAS Center Fribourg   (Switzerland)

Author keywords

Prevalence; Risk factors; Vulvar neoplasms; Wounds and injuries

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HEMATOMA; HEMIVULVECTOMY; HUMAN; LENGTH OF STAY; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; NECROSIS; PATIENT ASSESSMENT; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEROMA; SURGICAL INFECTION; TREATMENT DURATION; VULVA CANCER; VULVECTOMY; WOUND COMPLICATION; WOUND DEHISCENCE;

AGED; CROSS-SECTIONAL STUDIES; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; LYMPH NODE EXCISION; MEDICAL RECORDS; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURGICAL WOUND INFECTION; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VULVAR NEOPLASMS;

EID: 77952265512     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181d92723     Document Type: Article

References (21)

1. Cancer Research UK. Vulva Cancer incidence statistics. [Cancer Research UK]; September 05, 2008; Available from: http://info.cancerresearchuk.org/ cancerstats/types/vulva/incidence/. Accessed December 05, 2008.
2. Federation Internationale de Gynecologie et Obstetrique FIGO, American Joint Committee on Cancer's TNM classifications. Vulvar Cancer Treatment. TNM Category/FIGO Stage. [National Cancer Institute]; December 03, 2008; Available from: http://www.cancer.gov/cancertopics/pdq/treatment/vulvar/ HealthProfessional/page4. Accessed, March 24, 2008.
3. Vasel-Biergans A, Probst W. Wundversorgung für die Pflege. Ein Praxisbuch. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 2005.
4. Uyl-De Groot CA, Hartog JG, Derksen JG, et al. Cost-effectiveness and quality of life of granulocyte-colony stimulating factor (filgrastim) after radical vulvectomy and bilateral inguino-femoral lymphadenectomy: results of a randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2004;114:77-82.
5. Dardarian TS, Gray HJ, Morgan MA, et al. Saphenous vein sparing during inguinal lymphadenectomy to reduce morbidity in patients with vulvar carcinoma. Gynecol Oncol. 2006;101:140-142.
6. Gaarenstroom KN, Kenter GG, Trimbos JB, et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer. 2003;13:522-527.
7. Hanprasertpong J, Chichareon S, Wootipoom V, et al. Clinico-pathological profile of vulva cancer in southern Thailand: analysis of 66 cases. J Med Assoc Thai. 2005;88:575-581.
8. Khobjai A, Srisomboon J, Charoenkwan K, et al. Radical surgery for T1 and T2 squamous cell carcinoma of the vulva through separate incisions. J Med Assoc Thai. 2005;88: S75-S81.
9. Leminen A, Forss M, Paavonen J. Wound complications in patients with carcinoma of the vulva. Comparison between radical and modified vulvectomies. Eur J Obstet Gynecol Reprod Biol. 2000;93:193-197.
10. Paley PJ, Johnson PR, Adcock LL, et al. The effect of sartorius transposition on wound morbidity following inguinal-femoral lymphadenectomy. Gynecol Oncol. 1997;64:237-241.
11. Rouzier R, Haddad B, Dubernard G, et al. Inguinofemoral dissection for carcinoma of the vulva: effect of modifications of extent and technique on morbidity and survival. JAm Coll Surg. 2003;196:442-450.
12. Sultana N, Naz S. Radical vulvectomy by two different surgical incisions. J Pak Med Assoc. 2007;57:74-77.
13. Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008;26:884-889.
14. Carlson JW, Kauderer J, Walker JL, et al. A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study. Gynecol. Oncol. 2008;110:76-82.
15. Gottrup F, Melling A, Hollander DA. An overview of surgical site infections: aetiology, incidence and risk factors. [World Wide Wounds]; September 2005; Available from: http://www.worldwidewounds.com/2005/september/ Gottrup/Surgical-Site-Infections-Overview.html. AccessedApril30, 2007.
16. Asmussen PD, Sollner B. Die Prinzipien der Wundheilung. Embrach: Akademie fur zertifiziertes Wundmanagement; 2005.
17. Lippert H. Wundatlas. Kompendium der komplexen Wundbehandlung. 2nded. Stuttgart, New York: Thieme; 2006.
18. Arbeitsgemeinschaft für Gynäkologische Onkologie e. V. in der Deutschen Krebsgesellschaft e. V. (DKG) und in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG). Interdisziplinäre S2K-Leitlinie für die Diagnostik und Therapie des Vulvakarzinoms und seiner Vorstufen. [Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V.]; September, 2009; Available from: http://www.dggg.de/leitlinien/aktuelle- leitlinien/. Accessed January, 14, 2010.
19. Probst S, Bornhauser S. Konzept und Leitfaden für die Praxis. Pflege und Behandlung der malignen Wunde. Standard. Kleinandelfingen: Onkologiepflege Schweiz; 2007.
20. Mueller MD, Senn B, Eicher M, et al. Creating and Validating a Patient-Reported Instrument to Assess Symptom Experience Related to Surgical Wounds in Women With Vulvar NeoplasmsVa Mixed Methods Study. Bern: Krebsforschung Schweiz: KFS 02456-08-2009;2009:1-24.
21. De Hullu JA, Van der Avoort IA, Oonk MH, et al. Management of vulvar cancers. Eur J Surg Oncol. 2006;32:825-831.